myeloma-related kidney diseaseMultiple myeloma (MM) is the abnormal proliferation of plasma cells that leads to the production of monoclonal light chains. These light chains may cause renal disease by forming tubular casts (cast nephropathy), granular deposits (light chain deposition disease), or ...
Bi-Specific T-cell engager (BiTE).Teclistamab-cqyv(Tecvayli) is a bispecific T-cell engager that is prescribed when you have already been treated with at least four other therapies. It is a monoclonal antibody that targets BCMA. It can attach to both a T cell and a myeloma cell at th...
Kidney impairment: the kidneys may be damaged in multiple myeloma in a number of ways. Bone destruction by plasma cells leads to increased levels of calcium in the blood (hypercalcemia), which is harmful to the kidneys. In addition, the abnormal immunoglobulins produced by the plasma cells can ...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
The reversal of renal failure in multiple myeloma patients should be studied. At present, there is no specific treatment for myeloma kidney, and therapy is focused on controlling the tumor mass. There is substantial progress in the treatment of multiple myeloma with the introduction of new drugs ...
IGA MULTIPLE MYELOMA WITH ACUTE KIDNEY INJURY AND VASCULAR PURPURA, A RARE ASSOCIATION Acta Medica MarisiensisRoxana tefania, Gherghina EnacheGeorgiana, CoconaCocos, Ramona NinaDaniela, ChelaruOana, Catalina MihaelaLiliana, uElena, Ciciu
Toxic acute tubular necrosis following treatment with zolendronate (Zometa). Kidney Int 2003; 64: 281–289. Article CAS PubMed Google Scholar Durie BG, Kyle RA, Belch A, Besinger W, Blade J, Boccadoro M et al. Myeloma management guidelines: a consensus report from the Scientific Advisors...
Renal failure (RF) occurs in approximately 20-30% of multiple myeloma (MM) patients at diagnosis and in more than 50% of patients with advanced disease. The pathogenesis of RF is related to the production of monoclonal light chains that can damage either the tubule (myeloma kidney) or the ...
Multiple myeloma (MM), a plasma cell cancer, is associated with many health challenges, including damage to the kidney by tubulointerstitial fibrosis. We develop a mathematical model which captures the qualitative behavior of the cell and protein populat
Plasmapheresisis an uncommon treatment that can be used to manage something called myeloma kidney, a type of kidney failure that affects many people withmultiple myeloma. It separates outplasmafrom the rest of your blood. It's a way to remove abnormal proteins and other harmful substances from ...